Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common
cause of death within the next 10 years. The prognosis for this disease is poor despite …

Pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of all
pancreatic tumours, is a devastating malignancy with an extremely poor prognosis, as …

Late diagnosis contributes to pancreatic cancer (PaCa) dismal prognosis, urging for reliable,
early detection. Serum‐exosome protein and/or miRNA markers might be suitable …

Pancreatic ductal adenocarcinoma (PDAC) is usually detected late in the disease process.
Clinical workup through imaging and tissue biopsies is often complex and expensive due to …

Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with rising incidence and a
remarkable resistance to current therapies. The reasons for this therapeutic failure include …

Background Previous studies identified microRNAs (miRNAs) and messenger RNAs with
significantly different expression between normal pancreas and pancreatic cancer (PDAC) …

Pancreatic cancer (PC) is a leading cause of cancer related mortality on a global scale. The
disease itself is associated with a dismal prognosis, partly due to its silent nature resulting in …

Objective Tumour-associated macrophages (TAMs) play key roles in tumour progression.
Recent evidence suggests that TAMs critically modulate the efficacy of anticancer therapies …

Chimeric antigen receptor (CAR) T cell expansion and persistence emerged as key efficacy
determinants in cancer patients. These features are typical of early-memory T cells, which …

Background Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic
adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after …